# OnCo record menin-kmt2a (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/menin-kmt2a/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "menin-kmt2a" ;
  schema:name "Menin / KMT2A (HOXA9-MEIS1 axis)"@en ;
  schema:description "In some leukaemias a broken chromatin protein (KMT2A, once called MLL) or a mutant NPM1 keeps embryonic growth genes (HOXA9, MEIS1) switched on, so blood cells never mature. Both need a partner called menin to stay on the DNA. Menin inhibitors pull the plug and the cells mature; the first was approved in 2024."@en ;
  schema:url <https://onco.cc/pathways/menin-kmt2a/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/KMT2A> ;
  schema:citation <https://en.wikipedia.org/wiki/KMT2A> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:targets <https://onco.cc/targets/menin/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/hoxa9/>, <https://onco.cc/targets/meis1/> ;
  onco:drugs <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/> ;
  onco:pathways <https://onco.cc/pathways/epigenetic-reprogramming/> .